Despite decades of efforts, cancer metastasis remains largely incurable and causes about nine million deaths worldwide annually. Preventing or delaying metastasis holds tremendous potential for substantially prolonging the survival time and improving the quality of life of cancer patients. Nevertheless, there is a paucity of clinically actionable targets for inhibiting cancer metastasis as well as biomarkers for selecting appropriate patients and monitoring drug response. The Yang Laboratory focuses on addressing these pressing clinical needs.
Because proteins are the major functional molecules in cells and preferred targets for therapeutic agents and diagnostic tests, we develop multilevel proteomics methods and bioinformatic algorithms to comprehensively analyze protein abundance, post-translational modification and interaction. Coupling with in-depth phenotypic and mechanistic studies, we apply these leading-edge proteomics approaches to identify and credential high-value, clinically actionable targets and biomarkers. We also collaborate with physicians and oncologists to translate discoveries from bench to bedside to benefit cancer patients.
The Yang Laboratory is affiliated with the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Department of Surgery and Department of Biomedical Sciences.
I am currently an associate professor of surgery and biomedical sciences at Cedars-Sinai. My major research interests are to: develop leading-edge proteomics methods for the proteome-wide analysis of protein abundance, modification and interaction; identify novel, clinically actionable targets for inhibiting cancer metastasis and overcoming tumor resistance to standard therapies; understand the mechanisms of action of the newly discovered drug targets and their inhibitors; develop better and safer cancer therapies and discover novel biomarkers for selecting appropriate patient subpopulations and for monitoring drug response. In the near future, the research will provide personalized therapies to prevent or delay the emergence of metastasis in cancer survivors, and thus enable patients to live much longer and better lives."
Wei Yang, PhD
- Mechanisms and Targeting of RIPK2 in Cancer Metastasis and Drug Resistance
- Proteome-Scale Analysis of Protein Palmitoylation (S-Acylation)
- Complexome (Interactome) Profiling in Clinical Tissue Specimens
Collaborations & Resources
Meet Our Team
Learn more about the members of the Yang Laboratory, whose dedicated efforts lead to groundbreaking discoveries of high therapeutic and translational potentials.
Yan Y, Zhou B, Qian C, Vasquez A, Chatterjee A, Yuan X, Posadas E, Kyprianou N, Knudsen BS, Murali R, Gertych A, You S, Freeman MR, Yang W.
bioRxiv. Posted May 16, 2020.
Zhou B, Wang Y, Yan Y, Mariscal J, Di Vizio D, Freeman MR, Yang W.
Anal Chem. 2019 Aug 6;91(15): 9858-9866.
Zhou B, Yan Y, Wang Y, You S, Freeman MR, Yang W.
Clin Proteomics. 2019 Apr 13;16:15.
Mariscal J, Vager T, Kim M, Zhou B, Chin A, Zandian M, Freeman MR, You S, Zijlstra A, Yang W, Di Vizio D.
J Extracell Vesicles. 2020 Jun 10;9(1):1764192.
Contact the Yang Lab
8700 Beverly Blvd.
Davis Building, Room 5094B
Los Angeles, CA 90048